[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR092325A1 - Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit - Google Patents

Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit

Info

Publication number
AR092325A1
AR092325A1 ARP130101868A ARP130101868A AR092325A1 AR 092325 A1 AR092325 A1 AR 092325A1 AR P130101868 A ARP130101868 A AR P130101868A AR P130101868 A ARP130101868 A AR P130101868A AR 092325 A1 AR092325 A1 AR 092325A1
Authority
AR
Argentina
Prior art keywords
seq
kit
formulations containing
containing anti
dll4 antibodies
Prior art date
Application number
ARP130101868A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR092325(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR092325A1 publication Critical patent/AR092325A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Reivindicación 1: Una formulación farmacéutica que comprende: (i) un anticuerpo que se une específicamente a ligando tipo d humano 4 (Dll4); (ii) un amortiguador a pH de 6,0 ± 0,5; (iii) un cosolvente orgánico; y (iv) dos estabilizadores térmicos. Reivindicación 2: La formulación farmacéutica de acuerdo con la reivindicación 1, en donde el anticuerpo comprende una HCDR1 de SEC ID Nº 2, una HCDR2 de SEC ID Nº 3, una HCDR3 de SEC ID Nº 4, una LCDR1 de SEC ID Nº 6, una LCDR2 de SEC ID Nº 7 y una LCDR3 de SEC ID Nº 8. Reivindicación 3: La formulación farmacéutica de acuerdo con la reivindicación 1 o la reivindicación 2, en donde el anticuerpo comprende una HCVD de SEC ID Nº 1 y una LCVD de SEC ID Nº 5.
ARP130101868A 2012-05-31 2013-05-29 Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit AR092325A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261653478P 2012-05-31 2012-05-31

Publications (1)

Publication Number Publication Date
AR092325A1 true AR092325A1 (es) 2015-04-15

Family

ID=48670784

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101868A AR092325A1 (es) 2012-05-31 2013-05-29 Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit

Country Status (29)

Country Link
US (1) US9675692B2 (es)
EP (1) EP2854849B1 (es)
JP (1) JP6144758B2 (es)
KR (1) KR20150033615A (es)
CN (1) CN104349791A (es)
AR (1) AR092325A1 (es)
AU (1) AU2013267301B2 (es)
BR (1) BR112014028997A2 (es)
CA (1) CA2872275C (es)
CL (1) CL2014003237A1 (es)
CO (1) CO7151478A2 (es)
DK (1) DK2854849T3 (es)
EA (1) EA029779B1 (es)
ES (1) ES2668900T3 (es)
HK (1) HK1207305A1 (es)
IL (1) IL235468A0 (es)
LT (1) LT2854849T (es)
MA (1) MA37645B1 (es)
MX (1) MX357146B (es)
NO (1) NO2887943T3 (es)
NZ (1) NZ702288A (es)
PH (1) PH12014502429A1 (es)
PL (1) PL2854849T3 (es)
PT (1) PT2854849T (es)
SG (1) SG11201407171XA (es)
SI (1) SI2854849T1 (es)
TW (1) TWI609696B (es)
UY (1) UY34842A (es)
WO (1) WO2013181486A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2488204B1 (en) 2009-10-16 2016-04-06 Oncomed Pharmaceuticals, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
DK2758073T3 (en) 2011-09-23 2019-01-14 Oncomed Pharm Inc VEGF / DLL4 BINDING AGENTS AND APPLICATIONS THEREOF
PT3212233T (pt) 2014-10-31 2020-07-16 Oncomed Pharm Inc Terapia combinada para o tratamento de doenças
JP6781508B2 (ja) * 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
EP3781192A1 (en) * 2018-04-16 2021-02-24 Merck Patent GmbH Additives for protein formulations to improve thermal stability
UA128098C2 (uk) 2019-02-18 2024-04-03 Елі Ліллі Енд Компані Водна фармацевтична композиція антитіла проти il-17a
KR20230035595A (ko) * 2020-07-08 2023-03-14 리제너론 파아마슈티컬스, 인크. 항-ctla-4 항체를 함유하는 안정화된 제형

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
IL133220A0 (en) 1997-06-13 2001-03-19 Genentech Inc Stabilized antibody formulation
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
ES2644275T3 (es) 2000-08-11 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen anticuerpos
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
US8840884B2 (en) 2002-02-14 2014-09-23 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
HUE030579T2 (en) 2003-04-04 2017-05-29 Genentech Inc High Concentration Antibody And Protein Products
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ES2633574T3 (es) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
WO2008049897A1 (en) 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2010102241A1 (en) 2009-03-06 2010-09-10 Genentech, Inc. Antibody formulation
EP2488204B1 (en) * 2009-10-16 2016-04-06 Oncomed Pharmaceuticals, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
DK3721904T3 (da) 2009-11-20 2021-11-15 Biocon Ltd Formuleringer af t1h-antistof
EP3680253A3 (en) * 2010-03-02 2020-09-30 AbbVie Inc. Therapeutic dll4 binding proteins
MX344294B (es) * 2010-10-06 2016-12-13 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).

Also Published As

Publication number Publication date
PH12014502429B1 (en) 2015-01-12
EP2854849A1 (en) 2015-04-08
EA201492186A1 (ru) 2015-08-31
MX357146B (es) 2018-06-28
WO2013181486A1 (en) 2013-12-05
PT2854849T (pt) 2018-05-09
TW201400130A (zh) 2014-01-01
CN104349791A (zh) 2015-02-11
CO7151478A2 (es) 2014-12-29
SI2854849T1 (en) 2018-05-31
MA37645A2 (fr) 2016-08-31
CA2872275A1 (en) 2013-12-05
MA37645B1 (fr) 2018-10-31
IL235468A0 (en) 2014-12-31
PH12014502429A1 (en) 2015-01-12
CL2014003237A1 (es) 2015-07-10
BR112014028997A2 (pt) 2017-07-25
JP6144758B2 (ja) 2017-06-07
US20130323260A1 (en) 2013-12-05
PL2854849T3 (pl) 2018-07-31
LT2854849T (lt) 2018-05-10
HK1207305A1 (en) 2016-01-29
SG11201407171XA (en) 2014-11-27
EP2854849B1 (en) 2018-02-28
TWI609696B (zh) 2018-01-01
US9675692B2 (en) 2017-06-13
NO2887943T3 (es) 2018-05-05
NZ702288A (en) 2016-12-23
CA2872275C (en) 2021-05-18
MA37645A3 (fr) 2017-07-31
MX2014014363A (es) 2015-02-05
EA029779B1 (ru) 2018-05-31
AU2013267301A1 (en) 2014-12-18
UY34842A (es) 2013-12-31
ES2668900T3 (es) 2018-05-23
JP2015520173A (ja) 2015-07-16
DK2854849T3 (en) 2018-04-30
AU2013267301B2 (en) 2018-02-08
KR20150033615A (ko) 2015-04-01

Similar Documents

Publication Publication Date Title
AR092325A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
NZ630885A (en) Antibody formulation
PE20141151A1 (es) Proteinas de union al antigeno cd27l
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
PE20130226A1 (es) Anticuerpos hacia gdf8 humano
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
PE20181090A1 (es) Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
HRP20171964T1 (hr) Kombinacije i njihova upotreba
AR071891A1 (es) Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
PE20091261A1 (es) Anticuerpos anti-hepcidina
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ731735A (en) Anti-pd-1 antibodies and methods of use thereof
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
AR089787A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-ang2
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6
NZ719036A (en) Anti-pdl1 antibody formulations
NZ602054A (en) Anti-nerve growth factor (ngf) antibody compositions
PE20150159A1 (es) Composiciones y metodos para anticuerpos que actuan sobre el factor p
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
AR081434A1 (es) Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure